West Pharmaceutical stock (US9523901012): Morgan Stanley lifts price target as shares hover near USD 320

West Pharmaceutical, a US-based supplier of injectable drug packaging and delivery components, stayed in focus on the New York Stock Exchange on 05/29/2026 after Morgan Stanley raised its price target on the stock to USD 325 while maintaining an equal-weight rating, underscoring ongoing investor debate around valuation in the United States healthcare equipment sector.MarketBeat as of 05/29/2026

According to an alert summarizing the 05/29/2026 report, Morgan Stanley increased its target from USD 315 to USD 325 for West Pharmaceutical Services (ticker WST) and kept an equal-weight rating, signaling a neutral stance on the shares even as they trade close to the revised objective.GuruFocus as of 05/29/2026

The stock traded at about USD 320 in New York midday on 05/29/2026, leaving only limited nominal upside to the new target price and placing the move more in the context of fine-tuning assumptions than a wholesale shift in the US bank’s view of the company’s fundamentals.MarketBeat as of 05/29/2026

The company, which is headquartered in Exton, Pennsylvania, trades its primary listing on the NYSE under the symbol WST, making it part of the US healthcare equipment universe that many domestic and international investors follow as a proxy for demand in biologics, vaccines and other injectable therapies.Invezz as of 05/30/2026

In Germany, the shares are also available via secondary venues such as Tradegate, where they give euro-based investors access to the same US-listed equity, albeit typically with lower liquidity and wider spreads than on the NYSE, which remains the core trading venue for price discovery.Invezz as of 05/30/2026

The Target move from Morgan Stanley on 05/29/2026 follows a period in which West Pharmaceutical has seen its share price fluctuate alongside broader US medtech and life sciences tools peers, with investors weighing resilient demand for injectable drug delivery components against concerns about pricing, capital expenditure cycles and macro conditions in key markets.

As of: 30.05.2026

By the editorial team - specialized in equity coverage.

West Pharmaceutical: core business model

West Pharmaceutical focuses on designing and supplying specialized components and systems that enable pharmaceutical and biotech companies to safely package, seal and administer injectable medicines, with revenue largely driven by recurring demand for high-value proprietary elastomer and delivery solutions.

Insider activity and ownership structure

Recent regulatory filings and ownership data indicate that West Pharmaceutical’s shareholder base is dominated by large institutional investors, including US mutual funds and asset managers that typically focus on healthcare growth and quality franchises, which can contribute to relatively stable but valuation-sensitive demand for the stock.Invezz as of 05/30/2026

Form 4 disclosures filed with the US Securities and Exchange Commission over the past months show a mix of routine stock option exercises and scheduled share sales by executives, patterns that generally reflect compensation structures rather than clear directional views, while no large new insider purchases or block disposals have been highlighted in the latest available disclosures.SEC filings access as of 05/30/2026

Conclusion

The 05/29/2026 decision by Morgan Stanley to raise its price target on West Pharmaceutical to USD 325 while keeping an equal-weight rating highlights how closely US analysts are tracking the stock’s valuation as it trades around USD 320 on the NYSE.

For investors, the combination of a price level near the updated target, a business model tied to structural demand for injectable drug delivery components and a shareholder base dominated by institutions and routine insider activity helps frame the current market narrative without providing a clear directional signal.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.